Formulary Switch From Ibrutinib to Zanubrutinib Yields Positive Safety, Efficacy Data

A real-world report showed the safety and efficacy of zanubrutinib after a community oncology practice replaced ibrutinib with the newer Bruton tyrosine kinase inhibitor on its formulary.

Related Keywords

United States , American , Zanubrutinib Brukinsa , American Society Of Clinical Oncology , American Society , Clinical Oncology , Kaiser Permanente Northern California , Image Credit ,